The Guardant360^® assay is a breakthrough liquid biopsy that provides fast, accurate and comprehensive genomic results from a simple blood draw in approximately seven days upon receipt in the US laboratory. Since its launch in 2014, the Guardant360^® assay has been ordered by more than 6,000 oncologists over 100,000 times for patients with advanced cancer to help select treatment.

GuardantOMNI™, launched in 2017, is designed for biopharmaceutical customers to use as a comprehensive genomic profiling tool to help accelerate clinical development programs in immuno-oncology and targeted therapy.